CLINICAL_TRIALS
trial_result
· 2019-02-12
Clinical Trial Update: A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]
Summary
Completed Phase 1 study evaluating quizartinib (AC220) given after stem cell transplant in patients with acute myeloid leukemia.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Daiichi Sankyo | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: COMPLETED